How WuXi AppTec Addresses the Challenges of Steroid Drug Discovery and Development

Steroid compounds hold an important position in modern drug discovery and development, from the introduction of cortisone in the 1940s for rheumatoid arthritis to the advent of the oral contraceptive pill, which transformed reproductive health and the lives of millions of people. Today, steroids remain widely used in the treatment of cancer, immune disorders, and metabolic diseases.

However, the development and manufacturing of steroid compounds present distinct challenges as molecular structures become increasingly complex. First, commercially available steroid intermediates are largely limited to conventional core scaffolds, while customized intermediates suitable for novel structures remain scarce, complicating synthetic route design and process scale-up. Second, steroid scaffolds often contain multiple contiguous stereocenters, making it difficult to achieve precise regioselectivity and stereoselectivity at specific positions. These challenges can increase purification requirements during early development, promote side reactions during scale-up, and extend the time needed for impurity identification and control. 

Image source: 123RF

Developing Proven Capabilities in Steroid Chemistry 

More than a decade ago, WuXi AppTec's Research Chemistry Services (RCS) began developing specialized capabilities in steroid chemistry to address the synthetic and process challenges associated with structurally complex steroid molecules. Building on this experience, RCS has established a comprehensive steroid chemistry platform covering discovery, optimization, process development, and large-scale production. Today, the platform has synthesized over 10,000 steroid molecules. 

To enable the construction and modification of complex steroid scaffolds, RCS has established over 20 methods for controlling stereochemistry at specific positions. These capabilities are complemented by customized route design and access to a diverse range of advanced steroid intermediates, supporting activities such as hit-to-lead optimization, novel scaffold development, and focused library generation. RCS also provides capabilities in synthetic route development, impurity and metabolite synthesis, isotope labeling, and absolute configuration determination. Together, these capabilities enable the systematic characterization and optimization of steroid candidates based on their structural and physicochemical properties. The platform supports compound synthesis and delivery at scales ranging from milligrams to kilograms, as well as early process development and scale-up, helping clients advance programs efficiently through successive stages of development.

In one project, a client sought support for a steroid molecule whose original synthetic route involved numerous steps, poor regioselectivity, and limited reproducibility during scale-up. RCS redesigned the route, reducing the total number of steps from 7 to 3 and more than doubling the overall yield. The team exceeded expectations and earned positive feedback from the client. Following completion of the project, the client engaged RCS for an additional and more technically challenging steroid synthesis program.

In another project, RCS combined its steroid chemistry platform with the use of a key steroid intermediate to complete the synthesis of a target compound in 23 days. Given that the industry-standard timeline is approximately two months, the synthesis timeline was significantly shortened.

These examples demonstrate how WuXi AppTec’s comprehensive steroid chemistry platform supports steroid drug development and how its integrated development capabilities align with industry needs.

Image source: 123RF

Extending Steroid Chemistry Capabilities to Emerging Therapeutic Modalities 

The value of steroid chemistry extends beyond the development of conventional steroid-based therapeutics. With their rigid polycyclic structures and distinctive physicochemical and biological properties, steroid scaffolds can serve as functional components in the design of emerging therapeutic modalities, helping researchers modulate molecular properties that may otherwise limit drug development.

New modalities, including targeted protein degraders, antibody-drug conjugates (ADCs), and oligonucleotide therapeutics, are expanding the range of addressable targets and therapeutic design strategies. In some of these molecules, steroid-derived fragments can be incorporated as structural or functional components to modulate stability, targeting, or delivery. The development of such molecules requires steroid chemistry capabilities that enable precise, highly selective derivatization at specific positions on structurally complex steroid scaffolds.

RCS's comprehensive steroid chemistry platform has evolved in response to the growing demands of these new modalities. It now supports the efficient and highly selective derivatization of steroid fragments used in ADCs and targeted protein degraders. In one case involving the development of an ADC payload based on a steroid scaffold, the platform delivered hundred‑milligram-scale compounds for validation and improved the overall yield through route optimization, demonstrating its ability to support steroid-containing new modalities from early design through scalable synthesis.

WuXi AppTec’s RCS integrates steroid chemistry with the development of innovative therapeutic modalities, supporting the design and synthesis of ADCs, targeted protein degraders, prodrugs, and nitrogen mustard derivatives that incorporate steroid-derived structural or functional components. The platform also draws on complementary capabilities in analytical services, reaction-condition screening, recrystallization, flow chemistry, photoredox chemistry, and electrochemistry to support the progression from molecular design to scalable synthesis. By integrating long-term experience, modular technical capabilities, and cross-platform synergy, the steroid chemistry platform provides clients with reliable, efficient, and scalable synthetic solutions, accelerating the R&D of complex steroids and novel conjugate molecules.

The continued development of RCS’s steroid chemistry capabilities reflects the broader evolution of WuXi AppTec’s integrated, end-to-end CRDMO model. Through ongoing technical refinement and cross-functional collaboration, RCS helps clients improve discovery and development efficiency, shorten project timelines, and obtain one-stop solutions covering molecular design, process development, and scale-up.

As increasingly complex steroid molecules and emerging therapeutic modalities create new development demands, WuXi AppTec will continue to leverage its integrated CRDMO platform to help clients advance innovative therapies for patients worldwide. 

Key Takeaways:

1. WuXi AppTec’s Research Chemistry Services (RCS) has built an integrated steroid chemistry platform covering early discovery, molecular optimization, process development, and large-scale manufacturing.
2. With more than a decade of experience and over 10,000 steroid compounds synthesized, RCS has developed extensive expertise in addressing the stereochemical and synthetic challenges associated with complex steroid molecules.
3. Capabilities in route development, impurity and metabolite synthesis, isotope labeling, and absolute-configuration determination support the systematic characterization and optimization of steroid candidates.
4. RCS combines specialized steroid chemistry expertise with modular technical capabilities and cross-platform collaboration to support the design, synthesis, optimization, and scale-up of complex steroid compounds and novel conjugates.
5. The platform applies steroid chemistry to emerging therapeutic modalities, supporting ADCs, targeted protein degraders, prodrugs, and nitrogen mustard derivatives that incorporate steroid-derived components, while drawing on complementary capabilities in analytical services, reaction-condition screening, recrystallization, flow chemistry, photoredox chemistry, and electrochemistry.